Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium.

about

Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium.

Item

http://www.wikidata.org/entity/Q55344504

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Myocardial T1 mapping and dete ...... ne and gadofosveset trisodium.

@en

Myocardial T1 mapping and dete ...... ne and gadofosveset trisodium.

@nl

type

Item

label

Myocardial T1 mapping and dete ...... ne and gadofosveset trisodium.

@en

Myocardial T1 mapping and dete ...... ne and gadofosveset trisodium.

@nl

prefLabel

Myocardial T1 mapping and dete ...... ne and gadofosveset trisodium.

@en

Myocardial T1 mapping and dete ...... ne and gadofosveset trisodium.

@nl

P1476

Myocardial T1 mapping and dete ...... ne and gadofosveset trisodium.

@en

P2093

A Bluemke David

http://www.w3.org/2001/XMLSchema#string

Christopher T Sibley

http://www.w3.org/2001/XMLSchema#string

Fabio S Raman

http://www.w3.org/2001/XMLSchema#string

Jacquin Jones

http://www.w3.org/2001/XMLSchema#string

Marcelo Souto Nacif

http://www.w3.org/2001/XMLSchema#string

Neville Gai

http://www.w3.org/2001/XMLSchema#string

Songtao Liu

http://www.w3.org/2001/XMLSchema#string

P2860

An open-source software tool for the generation of relaxation time maps in magnetic resonance imaging.

Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.

Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart.

Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.

Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.

Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease

Assessment of myocardial fibrosis with cardiovascular magnetic resonance.

T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison.

Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences.

P304

13-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/0100-3984.2016.0071

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rob J van der Geest

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29559761

http://www.w3.org/2001/XMLSchema#string

P932

5846320

http://www.w3.org/2001/XMLSchema#string